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A B S T R A C T
Therapeutic peptide, NuBCP-9 (N9) as a Bcl-2 functional converter, has been demonstrated to have the re-
markable anticancer efficiency in Bcl-2-abundant cancer. However, it faced technical challenges in clinical use,
such as the low bioavailability, the easily-destroyed bio-stability, and the insusceptibility to cellular interior.
With the potential of mesoporous silica nanoparticles (MSNs) as the promising delivery vehicle of therapeutic
macromolecules, we developed a kind of MSNs with the surface coating of folic acid (FA) for cancer cell targeting
and with the macropore loading of N9 peptide for cancer therapy. Our results showed that the functional MSNs
had the relatively greater biosafety than the naked MSNs in zebrafish models, leading to less than 30% embryo of
death at 200 μg/ml, which could further specifically target the folate receptor (FR)-overexpressed cervical cancer
HeLa cells instead of FR-negative normal embryonic kidney HEK 293T cells in a FA-competitive manner. N9
peptide with the delivery of functional MSNs could be internalized by HeLa cells, and co-localized with mi-
tochondria in a Bcl-2-dependent manner. Moreover, N9 peptide delivered by FA-modified MSNs displayed the
excellent anticancer efficiency with great selectivity, inducing approximately 52% HeLa cells into apoptosis. In
summary, our results illustrated the potential of functional MSNs with large pore size as an efficient nanocarrier
for the intracellular delivery of peptide drugs with targeting proteins to realize cancer therapy.
1. Introduction
The increasing cancer incidence and mortality rates make the pre-
vention, diagnosis and targeted therapy become badly urgent. There are
two main obstacles to the successful cancer treatment: the severe toxic
side effects and the cancer multidrug resistance (MDR) [1]. One of the
causes for cancer MDR is the anti-apoptotic protein such as B cell
lymphoma gene 2 (Bcl-2) [2]. Bcl-2 family proteins are important
regulators of the anti-apoptotic machinery and the mitochondrial outer
membrane potential (MOMP) [3]. The anti-apoptotic activity of Bcl-2
has been targeted by small drug molecules such as ABT-137, navitoclax,
Apogossypol, HA-14, anti-ycin A, Oblimersen sodium, Gossypol (AT-
101), ab-737 (ab-263), GX15-070, VENCLEXTA, etc., which are all in
the FDA approved clinical application or in trial [4]. Although many
Bcl-2 targeted drugs have been developed or are being developed, they
mainly inhibit the anti-apoptotic function of Bcl-2 by releasing the Bcl-2
gene as a Bcl-2 inhibitor [5].
Nur77 (also known as TR3 or NGFI-B) is a potent member of the
nuclear receptor superfamily that promotes apoptosis and can be
transferred from the nucleus to the mitochondria of different death
signals under stimuli [6]. NUBCP-9 (N9) is a short Nur77-derived
peptide containing 9 amino acids. It acts as a molecular recognition
switch that converts Bcl-2 from protectors to cancer killers by binding
to Bcl-2 loop, eliminating BH4 domain, exposing to BH3 domain, and
triggering a conformational change in Bcl-2. Its unique property is that
N9 not only antagonizes the function of Bcl-2 and induces Bcl-2 con-
formation to be transformed into a BH3-like molecule, but also inhibits
the survival function of its anti-apoptotic relatives such as Bcl-XL [6]. In
contrast with chemotherapeutics, therapeutic peptides targeting in-
tracellular protein displayed the superior anticancer efficiency with
great biosafety. However, the preclinical development of peptidyl drugs
for cancer treatment is extremely obstructed by their instability, poor
pharmacological properties, low bioavailability and poor cell pene-
trative capabilities in vivo [3]. The development of state-of-art nano-
medicines based on mesoporous silica nanoparticles (MSNs) is expected
to overcome the above difficulties in the application of peptidyl drugs
(e.g., N9). That's because MSNs are generally recognized as safe by FDA
and used as one of the most promising drug delivery carriers. Due to the
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tunable particle size (10-1000 nm) and pore diameter (2-20 nm) in wide
ranges, and the facile surface functionalization [7], MSNs nanocarriers
have a distinctively high payload of anti-cancer drugs and controllable
release feature, and can be easily modified with targeting (e.g., folic
acid, FA) and “stealth” molecules (e.g., polyethylene glycol, PEG) [8] to
be the smart bombs. However, the conventional MSNs usually pos-
sessed the small pore sizes, thus it is usually difficult to load the large
molecules. Moreover, it is a slow process to diffuse bio-macromolecules
through pores< 5 nm [9]. In sharp contrast, we have synthesized the
MSNs with small sizes of< 50 nm and large enough pore channels
of> 5 nm to transport the Bcl-2 functionally transformed peptides into
mitochondria of tumor cells [10].
Folate receptors (FR), a glycophosphatidylinositol-linked cell sur-
face receptor, as the targets are usually over-expressed on the surface of
most solid tumor cells and relatively low-expressed on normal cells
[11]. Therefore, many scientific experiments on utilizing FA (or other
substances similar to FA) as a targeting ligand molecule to modify the
drug delivery vector for achieving the specific localization of tumor
cells in vivo and releasing the anticancer drugs to kill cancer cells have
been reported [12,13]. In this study, we presented an exciting strategy
to achieve the dual targeting outcomes by modifying the large pore
sized-MSNs surface with FA as the active targeting ligand and en-
capsulating a Bcl-2-converting peptide (N9) as a mitochondria targeting
agent [14]. The effective loading of N9 will be achieved through the
macropores of MSNs, and the specific targeting FR-positive tumor cells
to avoid toxicity will be obtained by the FA binding of MSNs surface.
The cell toxicity and apoptosis assays of N9 peptide were also carried
out in FR-positive human cervical cancer HeLa cells and FR-negative
human embryonic kidney HEK293T cells, and the biosafety of MSNs
nanocarriers was investigated in zebrafish models. This study will
provide a strategy for dual targeting tumor therapy with Bcl-2 poly-
peptides via the design of functional macroporous silicon-based nano-
materials.
2. Results
2.1. Characterization of well-ordered MSNs with FA functionalization and
peptide loading
The N9 peptide was reported to play the apoptosis-inducing func-
tion via targeting mitochondria and converting Bcl-2 conformation, so a
small enough particle size is an important prerequisite for MSNs deli-
vering peptide to the designated mitochondrial position. The large pore
sized- and small particle sized- MSNs were synthesized as we previously
reported [10]. Dynamic light scattering (DLS) measurement showed
that the average hydrodynamic diameter of MSNs in pure water was
108 nm corresponding to 0.18 g triethanolamine (TEA) (Fig. 1H). Both
scanning electron microscopy (SEM) and transmission electron micro-
scopy (TEM) analyses displayed that the synthesized MSNs had the
average particle size of 33 nm while possessed the approximately
spherical morphology with the dendrimer-like mesoporous internal
structure (Fig. 1A, D). When the surface was modified with amine
functionality/targeting moiety or the pore was encapsulated with
peptide drugs, there was no obvious change in surface morphology and
particle size (Fig. 1B, C, E). But if N9 peptide was conjugated onto
MSNs-FA surface, there was a bit of increase in particle size (36 nm) as
shown in Fig. 1F. The DLS measurement also confirmed the successful
surface functionalization at each step, accompanied by the surface
charge of MSNs was from negative (-32.8 ± 0.95mV) to positive
(29.9 ± 0.51mV), then to positive (23.0 ± 1.94mV) (Fig. 1G). When
dispersed in ddH2O, though MSNs had the uniform size distribution, the
DLS diameter was increased from 108.1 ± 0.55 nm to
143.1 ± 4.52 nm after surface was decorated with FA molecules
(Fig. 1H and I). The hydrophilic diameter seemed to be larger than the
SEM diameter, which might be due to the aggregation phenomenon
because of the hydrate layers on the particle surface. Nitrogen
adsorption-desorption isotherm measurement further demonstrated
that MSNs possessed the relatively low specific surface areas of 137-
151m2/g and pore volume of 0.4-0.6 ml/g, but the large well-defined
pore size of 10-15 nm, indicating their macroporous characters (Fig. 1J-
L). Relative to the conventional MSNs with small pore size (< 5 nm)
[15,16], our prepared MSNs had the macropore size, which would
contribute to the enhanced loading of Bcl-2-converting peptide, even
other macromolecules, such as nucleic acid and protein drugs.
2.2. Verification of the surface functionalization and peptide release
To confirm the synthesis of peptide-delivered MSNs-targeted de-
livery system, various techniques were used. The signal resonating
between 6.59 and 8.66 ppm were largely assigned to the characteristic
aromatic protons on FA from the surface of MSNs, which further con-
firmed the successful functionalized silica (Fig. S1). The successful
functionalization of MSNs with FITC and decoration with Rhodamine B-
labeled N9 (i.e., N9-RB) could also be demonstrated from the unique
fluorescence images of the green and red colors from N9-RB@FITC-
MSNs-FA in pure water (Fig. 1M and N). The loading efficiency of N9
was 8.2% (wt%). The in vitro release studies showed that there wasn't a
pH-sensitive release behavior of FITC-labeled N9 peptide (i.e., N9-FITC)
from the pores of MSNs-FA. As shown in Fig. 1 O, the release behavior
was displayed with a typical three-phase character containing a burst
release before 10 h, followed by a slow release over 48 h, then a steady
release over 96 h. It was found that 10.62% and 16.33% of N9 were
respectively released by 10 h and 96 h when the nanoparticles were
incubated in PBS at pH 7.4, whereas, only 0.18% and 1.49% were re-
leased at pH 5.0. The initial burst release of peptide before 10 h might
be attributed to the presence of N9-FITC peptides absorbed on the
surface of the MSNs-FA nanoparticles. Moreover, the lack of acid-re-
sponsive release characteristics of peptide from the macropores of
MSNs-FA nanoparticles, consistent with previously reported [3], might
be related to the theoretical isoelectric point (PI= 9.76) of N9 peptide,
which would largely contribute to its less degradation and enhanced
stability in cells.
2.3. Selective cell-targeting and internalization of functional nanoparticles
mediated by folate receptor
N9 peptide could be attached on the surface of MSNs or be en-
capsulated into the macropores of MSNs. To compare the cell-pene-
tration capability of peptide with the aid of MSNs in different carrying
ways, the cellular internalization behaviors were accordingly in-
vestigated under a laser confocal microscope. After 3 h of incubation,
we found that N9 peptide could be taken by MSNs-FA into cytoplasm of
HeLa cells in N9-loading way instead of conjugating way (Fig. S2).
Thus, N9 peptide was prone to be loaded into the macropores of MSNs
for the following experiments. In order to verify the feasibility of tar-
geted drug delivery carriers for the effective cancer targeting and cel-
lular internalization, FA-modified MSNs were attached with fluorescein
to provide a means for fluorescent tracing. FR-negative HEK293T and
-positive HeLa cells were both used to show the target specificity of
MSNs-FA in this assay. After exposed to MSNs-FA nanoparticles for
different times (0, 1, 3, 6, 12 h), cells were labeled with mitotracker and
DAPI for taking fluorescence images. The result showed that in the first
3 h, no or less green fluorescence color was observed from the cells,
indicating that the incubation time is not enough for MSNs penetrating
cell membrane. With the incubation time prolonged, MSNs-FA could
specifically bind HeLa cell membrane at 6 h, then penetrate the cell
membrane into cytoplasm and distribute in mitochondria, especially
after 12 h (Fig. 2A, C). The co-localization of particle with mitochondria
was demonstrated by the merged green-red fluorescence color. The
reason why MSNs-FA nanoparticles were distributed in mitochondria
might be attributed to the FA/FR-mediated endocytosis effects. How-
ever, similar phenomenon wasn't found in HEK293T cells even at 12 h
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(Fig. 2B). It seemed that HeLa cancer cells were more prone to be bound
by FA-modified MSNs than HEK293T, which was up to the over-ex-
pression level of folate receptor on cancer cells not on normal cells. The
obtained results demonstrated that the introduction of FA ligand could
significantly improve specific targeting of MSNs to HeLa cells over
HEK293T normal cells, thereby facilitating the N9 peptide endowed by
target cells and released to the mitochondrial location for the following
cell apoptosis function.
In order to confirm the FR-mediate endocytosis of functional MSNs,
HeLa cells were treated with FA prior to FITC labeled-MSNs-FA in-
cubation. The flow cytometry experiment was carried out to quantify
the mean fluorescence intensity from HeLa cells. Without FA
competition, the binding capacity of MSNs-FA was increased with the
incubation time prolonged from 3 h to 24 h, which was determined by
the improved fluorescence intensity of FITC from cells. The cellular
uptake efficiency reached about 85% after 24 h of incubation, which
was calculated based on the percentage of FITC-positive cells (Fig. 2D).
However, in the presence of free FA, the decreased fluorescence in-
tensity or the reduced percentage of FITC-positive cells was observed,
about by 10%-20%, demonstrating an inhibition of cellular uptake by
free FA (Fig. 2D). The FR competition experiments further confirmed
the specific FR-mediated targeting of MSNs-FA for FR-positive cancer
cells.
Fig. 1. Physicochemical characterization of FA-modified macroporous silica nanoparticles (MSNs) encapsulated with N9 peptide. The morphological and zeta
potential changes of MSNs before and after a series of surface functionalization and loading with N9 peptide analyzed both by SEM (A,B,C) and DLS (G,H,I).
Confirmation of MSNs (D) encapsulated with (E) or attached with (F) N9 peptide by TEM images. Nitrogen desorption isotherms displaying the distribution of pore
size and pore volume of MSNs (J,K,L). Fluoresence images confirming FITC-labeled MSNs-FA nanoparticles (M) encapsulated with RB-labeled N9 peptide (N) in pure
water. Cumulative release curves of N9 peptide from the pores of MSNs-FA nanoparticles at different pH values (O).
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2.4. Time course-dependent cell endocytosis, uptake and mitochondrial
localization of peptide
Accumulation on cellular mitochondria is the necessary prerequisite
for the apoptosis function of N9 peptide. In view of this, flow cytometry
was carried out to compare the delivery efficiency of N9@MSNs-FA into
FR-negative (HEK293T) and -positive (HeLa) cells. As shown in Fig. S3,
MSNs-FA nanoparticles and N9 peptide could be selectively taken up by
HeLa not HEK293T cells, and their cellular uptake efficiencies respec-
tively reached 22.7% and 3.3% compared to the control cells based on
the percentage of FITC- and RB- positive cells. Microscopic analysis was
then performed on HeLa cells to investigate the capacity of MSNs-FA
delivering N9 peptide to the designated mitochondrial position.
Given that the binding of N9 with Bcl-2 protein on mitochondrial
was the key point for converting Bcl-2 from a protector to a killer of
cancer cells, the studies on the co-localization of N9-loaded MSNs-FA
with mitochondria and the endogenous Bcl-2 were respectively eval-
uated in this assay. Confocal microscope analysis was made after HeLa
cells treatment with N9@MSNs-FA for 12 and 24 h followed by mito-
tracker labeling or immunofluorescence staining of the intracellular
protein Bcl-2. The images displayed that the merged yellow-fuchsia
fluorescence predicted a high level of co-localization between N9@
MSNs-FA (yellow) and Bcl-2 (fuchsia). With the incubation time pro-
longed from 12 h to 24 h, a significant binding between N9@MSNs-FA
and Bcl-2 was observed and the internalization of nanoparticles to cell
nucleus was even found from the merged fluorescence color (yellow-
blue). Thus, the synthesized N9@MSNs-FA showed the relatively great
cell-penetration capacity, which was consistent with what we
Fig. 2. LSCM and FACS analyses of cell targeting and cell internalization behaviors mediated by FITC-labeled MSNs-FA nanoparticles. A, Penetration and inter-
nalization behaviors of FITC-MSNs-FA in HeLa cancer cells with incubation time prolonged from 1 h to 12 h. B-C, Selective targeting and internalization behaviors of
FITC-MSNs-FA nanoparticles in FR-negative HEK293T (B) and FR-positive HeLa (C) cells after 12 h of their co-incubation. DAPI (blue) and mitochondrial probe (deep
red) were respectively used to show the presence of cell nucleus and mitochondria. Note, scale bar: 25 μm. D, Flow cytometric analysis of the competitive cellular
uptake behaviors mediated by FA in different time intervals. HeLa cells were treated with or without 1mM FA for 30min, followed by FITC-MSNs-FA incubation for
different times. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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previously reported [10]. Taken together, these observations will con-
tribute to the induction of apoptosis by N9. Especially at 12 and 24 h,
the N9 peptide could be effectively delivered to mitochondria accom-
panied by MSNs-FA nanoparticles, which was the result of the fluor-
escence overlap between green (MSNs), red (N9), and deep-red (mi-
tochondria) spots (Fig. 3A).
As a Bcl-2 converter, N9 peptide derived from a Nur77 fragment
needs to interact with Bcl-2 and expose BH3 domain to make the pro-
apoptosis function. So whether N9 targeted mitochondria by binding
Bcl-2 was further investigated by us. Immunofluorescence experiments
showed that MSNs-FA nanoparticles (green fluorescence) could pene-
trate from cytomembrane to cell interior by FR-mediated cell en-
docytosis, and accumulate strongly in cytoplasm with incubation time
prolonged from 12 h to 24 h. N9 with red fluorescence labeling was able
to reach mitochondria and specifically bound with Bcl-2 protein after
12 h of incubation with the carrier of FA-targeted MSNs, the interaction
effect became more obvious especially at 24 h, which could be seen
from the merged fluorescence colors (Fig. 3B). The interaction between
N9 and Bcl-2 will pave the way for converting the anti-apoptotic
function of Bcl-2 in targeted cancer therapy.
2.5. Bcl-2-depdent co-localization of peptide with mitochondria
To examine whether mitochondria targeting by N9 peptide was
dependent on Bcl-2 expression, we carried out the similar experiments
in Bcl-2 gene-knocked out- HeLa cancer cells. The intracellular locali-
zation behavior was examined corresponding to different incubation
times. Confocal images showed that N9 peptide accompanied with FA-
modified MSNs could accumulate in cells with time prolonged from 1 h
to 24 h. The accumulation level on cytoplasm could be distinguished
either from the distance between N9/MSN and mitochondria, or the
merged yellow fluorescence intensities. We found that the intracellular
fluorescence intensity was enhanced with incubation time increased,
and the distance with mitochondria was reduced. However, the co-lo-
calization of N9 with mitochondria wasn't present even at 24 h (Fig. 4).
N9 peptide was more close to mitochondria with time prolonged,
however, it couldn't arrive the mitochondria without the presence of
Bcl-2. The above phenomenon collectively demonstrated that the ex-
pression of Bcl-2 was necessary for N9 peptide in mitochondria tar-
geting and even the final apoptotic effects. Bcl-2 is a major target of N9
peptide.
2.6. Inhibitory effects on cancer cell growth in vitro
To assess the selective cytotoxicity of N9@MSNs-FA, FA-positive
HeLa or negative HEK293T cells were treated with free N9, N9-loaded
MSNs-FA with vary concentrations (1-200 μg/ml) for 48 h to evaluate
the effects on cell proliferation. For comparison, N9 without cell-pe-
netrating peptide (CCPs) domain was used as the positive control. It
was found that free N9 hardly changed the cell activity due to its in-
accessibility to cell interior. In contrast, the substantial inhibition of cell
proliferation was largely associated with the N9-loaded MSNs-FA
(Fig. 5A-B). The results showed that the viability of HeLa cells could be
effectively decreased by N9-loaded MSNs-FA in a dose-dependent
Fig. 3. Microscopic analysis of the co-localization behaviors of fluorescence-labeled N9@MSNs-FA with mitochondria (A) or Bcl-2 protein (B) in HeLa cells after 12 h
or 24 h of co-incubation, respectively. Note, the green and red fluorescence colors, respectively, indicated the presence of MSNs-FA nanoparticles and N9 peptide
within cells. Scale bar: 25 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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manner. When the concentration of N9@MSNs-FA was increased from 1
to 200 μg/ml, the viability of HeLa cells was decreased sharply from
about 94.3% to 24.6% (Fig. 5B). As expected, N9-encapsulated MSNs-
FA had no apparent effect on HEK293T cell growth (Fig. 5A). The
reason why N9@MSNs-FA showed little improvement on the pro-
liferation of HEK293T cells might be deemed to the low expression of
folate receptor on cell membrane. When converting the action con-
centration of MSNs to the corresponding actual concentration of N9
based on the respective loading efficiency, N9 with the delivery of
MSNs-FA at the relatively less action concentrations had the more ef-
fective inhibitory effects on HeLa cells not HEK293T cells. The IC50
value of N9@MSNs-FA against HeLa cells was 32.83 μg/ml (equivalent
to 2.54 μM N9), which was nine times less than that against HEK293T
cells, further demonstrating the effective proliferation-inhibition cap-
ability of nanodrugs on target cancer cells. These results collectively
confirmed that N9 could be intracellularly delivered by MSNs-FA with
great selectivity.
2.7. Flow cytometric analysis of cell apoptosis
To evaluate the apoptosis effects of N9-encapsulated MSNs-FA on
HeLa cells, flow cytometric analysis was carried out on a Beckman
Coulter cytoflex with Annexin V-FITC/PI double staining method. The
percentage of apoptotic cells after 48 h-treatment with N9 or N9@
MSNs-FA was quantitatively calculated based on cells labeled with
Annexin V-FITC and/or PI in the sample groups relative to control one.
It was found that free N9 almost didn't produce cell apoptosis (3.7%),
which still kept more than 73% of survival for HeLa cells (Fig. 5C). In
contrast, on the normalization of N9 dose, N9-encaspulated MSNs-FA
displayed the discrepant anti-proliferation efficiency mediated by the
FA molecule on MSNs and the specific interaction between N9 and
intracellular Bcl-2 protein. When the concentration of N9@MSNs-FA
was 100 μg/ml, the total percentage of the apoptotic HeLa cells was
51.66% compared to control. Unexpectedly, N9 and N9@MSNs-FA
didn't show any apoptosis-inducing effect on HEK293T cells (Fig. 5C).
The above results demonstrated that MSNs-FA nanocarriers could take
actions in the final inhibitory effects of N9 on target cancer cell activity.
Fig. 4. The Bcl-2-dependent co-localization behaviors of N9-RB@FITC-MSNs-FA nanoparticles with mitochondria in Bcl-2 gene-knock out HeLa cells at different
incubation time intervals. Scale bar: 25 μm.
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2.8. Biosafety in Zebrafish models
Zebrafish embryos rather than mammalian models were employed
to evaluate the bio-toxicology of these functional MSNs [17-19], which
allowed the evaluation of the possible effects on lethality (acute toxi-
city) and hatchability. The acute assay was performed by incubating 20
zebrafish embryos of 48-hpf with MSNs-NH2 or MSNs-FA nanomaterials
in three different concentrations for measurement of the cumulative
mortality until at 72 h. It was clear that it might be safe for naked
MSNs-NH2 nanoparticles below the dose of 200 μg/ml, but at 200 μg/ml
MSNs-NH2 induced the zebrafish embryo to be dead in an incubation
time-dependent manner. The mortality rate reached 80% at 72 h. In
sharp contrast, after surface decoration with FA, MSNs-FA nano-
particles produced the less toxic to zebrafish embryos than MSNs-NH2,
which kept approximately 70% of embryo alive even after 72 h ex-
posure (Fig. 6A-C). Besides, the hatching rate was significantly im-
proved by MSNs-FA compared to MSNs-NH2. The Zebrafish embryos
treated with MSNs-FA nanoparticles hatched 70% at 72 h while only
20% embryos hatched in the MSNs-NH2-treated embryos (Fig. 6D).
Overall, the MSNs-FA nanoparticles as nanocarriers displayed the great
biosafety in vivo, which might be due to the biocompatible components
(e.g., FA) present on MSNs surface [20].
3. Discussion
Various stimuli-responsive multifunctional MSNs were developed as
drug nanocarriers for effective cancer therapy [21,22]. However,
compared to the conventional small pore-sized MSNs, the large pore-
sized MSNs exhibited the superior advantages on facilitating the cell
penetration and realizing the subcellular site-specific delivery of bio-
macromolecules (therapeutic peptide, protein, and nucleic acid)
[23,24]. In this study, we report the unique MSNs with macropores of
10-15 nm in diameter and successfully encapsulate a Bcl-2-converting
peptide (N9) into the pores with the loading efficiency of 8.2% (Fig. 1).
HeLa cells with elevated Bcl-2 and FR expression were selected as the
targeted cancer model in vitro. The surface functionalization of MSNs
with FA displayed the FR-mediated cancer cell targeting and en-
docytosis effects in HeLa cells (Fig. 2), which was similar as what
previously reported [12,13,25]. Besides, the amino groups of MSNs
nanoparticles were protonated at acidic endosomal pH, which disrupted
the endosome and promoted the escape of particles from endosome into
cytoplasm. The escape behavior was attributed to the “proton-sponge”
Fig. 5. The effect of N9 peptide on cell activity with the delivery of MSNs-FA nanoparticle. The selective cytotoxicity of N9-loaded MSNs-FA nanoparticles to FR-
negative (HEK293T, A) and positive cells (HeLa, B) at various nanoparticle concentrations ranging from 1 to 200 μg/ml after 48 h exposure. The comparison was
made between free N9 and N9@MSNs-FA. Symbol (###) indicates the very significant difference, p < 0.001. C, Analysis of the apoptotic effects on HEK293T and
HeLa cells selectively induced by N9-loaded MSNs-FA (100 μg/ml) nanoparticles after 48 h incubation. In these assays, free N9 peptide was used as the positive
control.
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or “endosome buffering” effects [26,27], which largely contributed to
the mitochondrial localization of the delivered N9 peptide by the above
functional MSNs (Fig. 3). Moreover, the mitochondrial localization is a
Bcl2-dependent manner (Fig. 4), which paved the way for the final cell
apoptosis effects (Fig. 5) via the specific interaction between N9 peptide
and Bcl-2 protein [6]. Besides, the in vivo biosafety of MSNs is another
key factor that limits its application. Various means were taken to re-
duce the severe and unpredictable toxicity risks including introduction
of disulfide bonds into the silica framework to achieve a stimuli-re-
sponsive biodegradation [28,29], or surface functionalization of MSNs
with biocompatible molecules to improve the biocompatibility. The
substitutes for CPPs by the functional MSNs avoided of the toxic side
effects of carriers and the non-selective transport of the delivered drugs
[3,30], which was both demonstrated in in vivo zebrafish embryo assays
(Fig. 6) and the in vitro cell targeting assays (Fig. 2). Zebrafish has been
widely recognized as an in vivo organism model for evaluating the nano
environment and human safety (EHS). The unique characters, such as
embryo transparency, high fecundity, low cost and short reproduction
time, potentiate zebrafish to be a model between the traditional cell
culture and mammalian [17-19]. The zebrafish assays not only provide
the validation for in vitro cell toxicity, but also the reference for in vivo
animal experiments. Thus, zebrafish was selected as a fast and valid in
vivo model to evaluate the biosafety of MSNs-FA nanoparticles in this
study. Collectively, our study demonstrated that the functional MSNs
with macropores had the significant promise in delivering peptide or
protein drugs for targeted cancer treatment. In spite of various nano-
formulations such as PLA-PEG-PPG-PEG tetrablock copolymer [3,31],
iron oxide-based nanoparticles (SPIONs) [30] and polyhydroxybutyrate
based nanoparticles (PHB-PEG) [32] were developed for intracellular
delivery of N9 peptide to treat cancer, employment of the dual targeting
inorganic silica nanoparticles with macropores as the novel carriers
hasn't yet been reported. In comparison with the above nanoformula-
tions, our delivery system showed the excellent anticancer efficacy with
great in vivo biosafety.
4. Conclusions
To be concluded, the novel macroporous silica nanoparticle plat-
form functionalized with folic acid was constructed by us for delivering
the Bcl-2-function converting peptide to treat cancer cells. The delivery
system had the dual functions with cancer cell membrane targeting
using FA-coupled MSNs and mitochondrial binding with the in-
tracellular delivery of the anti-cancer drug N9. The MSNs-FA nano-
particles showed great in vivo biosafety compared to the naked MSNs
without surface modification, which led to only less than 30% zebrafish
embryos to death even after 72 h of exposure. With the employment of
MSNs-FA nanocarriers, the cell-penetrative capabilities of N9 peptide
seemed to be largely enhanced with great selectivity, with over 50%
apoptotic HeLa cells after 48 h of co-incubation. In a word, the func-
tionalized macroporous silica nanoparticles with tumor targeting ef-
fects were successfully synthesized, which brought out the intracellular
delivery of Bcl-2-converting peptide in cervical cancers with great
specificity and biosafety. Our design could not only solve the difficulty
in intracellular delivery of therapeutic peptides to tumors, but also in-
crease the unique activities and functions of such hydrophilic bio-
macromolecule drugs. This study will provide the design strategy for
functional nanoparticles to solve the defects of therapeutic peptide/
protein drugs in cancer application.
5. Experimental section
5.1. Materials
FITC (purity, 96%) was purchased from Shanghai Macklin
Biochemical Co. Hexadecyl trimethyl ammonium chloride (CTAC,
≥98%) was purchased from Sinopharm Chemical Reagent Co. 3-
Fig. 6. Measurements of the in vivo biosafety of free
nanocarriers using zebrafish model. The mortality
rate of zebrafish embryos after individual incubation
with MSNs-NH2 and MSNs-FA nanoparticles at con-
centrations ranging from 10 to 200 μg/ml for
24 h,48 h or 72 h (A, B, C). The hatching rate of
zebrafish embryos after 72 h of exposure to various
concentrations of MSNs-NH2 and MSNs-FA nano-
particles (D). The significance analysis was per-
formed on the basis of the control (*) or MSNs-NH2
nanoparticles (#). Symbols (*, #) and (***, ###), re-
spectively, indicate statistically significant and very
significant difference.
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Aminopropyltriethoxysilane (APTES, ≥98%), Tetraethyl orthosilicate
(TEOS, 98%), FA (≥97%), 1-(3-Dimethylaminopropyl)-3 -ethylcarbo-
diimide hydrochlorid (EDC), N-Hydroxysuccinimide (NHS, 98%), DAPI
and [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrasodium bromide]
tetrazolium salt (MTT) were obtained from Sigma-Aldrich. TEA
(≥98%) was purchased from Aladdin. Bcl-2-converting peptide with or
without FITC labeling (FSRSLHSLL, N9 or N9-FITC, ≥98%) was syn-
thesized and purified by LifeTein (Beijing) Ltd, and N9 with RB labeling
(N9-RB) was from GL Biochem (Shanghai)Ltd. MitoTracker® Red and
Deep Red dyes were purchased from Life Company. Pure water was
used in all experiments. All other chemicals, unless otherwise specified,
were all purchased from Sinopharm Chemical Reagent Co., Ltd and
used without further purification.
5.2. Preparation and characterization of functional MSNs before and after
therapeutic peptide loading
5.2.1. Synthesis of MSNs and amino-modified MSNs
The large pore sized-MSNs were synthesized as we previously re-
ported [10,33], followed by the surface modification with amine
groups. Specifically, MSNs were dispersed in 50ml of ethanol and re-
fluxed for 4 h at 80-90 °C water bath, followed by the addition of 300 μl
APTES refluxed for another 24 h. Amine-modified MSNs were obtained
after repeated centrifugation and washing with ethanol and water to
remove the unreacted APTES and finally dispersed in water for lyo-
philization.
5.2.2. Synthesis of FA-functionalized MSNs loaded with therapeutic peptide
To obtain the functionalized MSNs with the ability of tumor tar-
geting, FA was covalently attached onto the surface of MSNs prior to
the loading of N9 peptide. FA (2mg) dissolved in 4ml of DMSO were
treated with excess molar ratios of EDC and NHS for 2 h in dark. The
active ester of FA was then mixed with the amine-terminated MSNs
(20mg) in the mixed solution of 6ml of DMSO and 18ml of DMF under
vigorous stirring for 24 h. The FA-attached MSNs were finally obtained
by repeated washing to remove the unreacted FA, and the excess EDC,
NHS, DMF and DMSO.
Anticancer peptide N9 was then conjugated onto the MSNs-FA
surface or loaded into the macropores of MSNs-FA. For the synthesis of
N9-MSNs-FA conjugates, N9 peptide was firstly dissolved in PBS (pH
7.4), and mixed with equal molar ratios of EDC and NHS for stirring.
After 1 h of activation, the N9 peptide solution was added with MSNs-
NH2 reacting for another 24 h at 25 °C. Excess EDC, NHS and N9 were
then removed by repeatedly washing and centrifugation with ddH2O for
several times. The conjugates were finally dispersed in water and stored
at 4°Cfor use. For the preparation of N9@MSNs-FA, the traditional
double emulsion/solvent evaporation (W/O/W) method was used.
1.4 mg of MSNs-FA was added into N9 solution in PBS (pH7.4) with a
mass ratio of M(N9):M(MSNs-FA) in 1:3 at room temperature stirring for
24 h in dark. After the reaction was completed, the mixture was cen-
trifuged at 14,000 rpm for 30min, the supernatant was collected and
the precipitate was washed with ddH2O. The above supernatant after
centrifugation was measured for the content of N9 by the BCA assay as
previously reported [32], and the drug loading of MSNs-FA was cal-
culated based on the obtained value. The encapsulation efficiency (EE)
and loading efficiency (LE) of N9 were calculated based on the fol-
lowing equations (1) and (2), respectively:
=
−Initial amount of N Amount of N in supernatant
Initial amount of N
%EE  
9 9
9
⁎100% 
(1)
=
−
−
Initial amount of N Amount of N in supernatant
Amount of N MSNs FA nanoparticles
%LE
9 9
9@
⁎100%
(2)
5.2.3. Release studies of N9 peptide from MSNs-FA nanoparticles
The release of N9-FITC from the macropores of MSNs-FA nano-
particles was performed in PBS solutions with pH values at 7.4, 6.8, and
5.0. N9-FITC@MSNs-FA nanoparticles (3.2 mg) at the N9 concentration
of 0.656mg/ml were respectively dialyzed in the above PBS solutions
(3 ml) and shaken in an incubator at 37 °C, 300 rpm to simulate the
physiological environments. At different time intervals (2, 4, 6, 10, 24,
48, 96 h), the dialysate (0.02 ml) was taken out and transferred for the
ultraviolent measurement at the wavelength of 490 nm on a microplate
reader (Promega Glomax ® Discover). At the same time, the same vo-
lumes of PBS solutions (0.02ml) with different pH values were re-
plenished to the corresponding N9-FITC@MSNs-FA solutions to keep
the total volume of the mixture constant. The curve of cumulative re-
lease percentage versus time was finally plotted based on the measured
results and the standard curve of N9-FITC solution.
5.2.4. Synthesis of FA-modified MSNs labeled with FITC
Briefly, FITC (1mg) was dissolved in 1ml of DMSO, and reacted
with MSNs-FA(4mg) under vigorous stirring overnight in dark. 1M
NaHCO3 was used to keep the reaction solution at pH 8.5. FITC-labeled
MSNs were then collected by centrifugation and washing with DMSO
and ddH2O for several times to remove the unreacted FITC. Finally, the
powder of MSNs-FITC was obtained by lyophilization.
5.2.5. Characterization of N9-loaded MSNs-FA nanoparticles
To confirm the successful conjugation of FA onto the surface of
MSNs, 1H NMR spectra was made on a Bruker 600MHz spectrometer to
show the characteristic proton peak of FA in DMSO‑d6 (dimethyl sulf-
oxide-d6) or MSNs-FA in CDCl3. DLS measurements were performed on
a Nano Zetasizer setup (Nano ZS90) to show the change in hydro-
dynamic diameters (diameter, nm) and surface charges (zeta potential,
mV) of MSNs nanoparticles in pure water before and after different
surface functionalization at the same concentration of 100 μg/ml. The
SEM and TEM images were respectively taken on a field emission scan
electron microscope (Zeiss, SUPRA 55) at 5.00 kV and a TEM (TecnaiG2
Spirit BioTwin) at 200 kV to determine the surface morphologies and
particle sizes of MSNs before and after FA attachment and N9 loading.
The dendrimer-like mesoporous structures of MSNs nanoparticles were
also observed from the SEM and TEM images. The large pore size
characters of MSNs were then determined by the nitrongen adsorption-
desorption isotherms, which were measured on a Micrometitics Tristar
II 3020system and calculated both by the BarretteJoynereHalenda
(BJH) and Brunauer_Emmett_Teller (BET) methods. The fluorescence
images were also taken under a fluorescence inverted microscope (Zeiss
Axio Observer A1) to further verify whether RB-labeled N9 peptide was
successfully encapsulated into the macropores of FITC-labeled MSNs-FA
nanoparticles.
5.3. Cell culture
Human cervical cancer HeLa cells and Human emborynic kidney
HEK293T cells were respectively cultured in MEM and DMEM mediums
supplemented with 10% fetal bovine serum, 100 units/ml penicillin,
and 100mg/ml streptomycin. All the cell lines above were grown at
37°Cin a humidified atmosphere of 5% CO2 incubator. When reached
the confluence of 70-80%, cells were harvested using 0.25% trypsin and
re-suspended in fresh medium for subsequent experiments.
5.4. Selective and competitive binding of FITC-MSNs-FA nanoparticles
To confirm the binding specificity of FA-coated MSNs to target
cancer cells, FR-positive and negative HeLa and HEK293T cells were
used in this assay. The adherent cells on coverslip-coated 24-well plates
were respectively incubated with FITC-labeled MSNs-FA nanoparticles.
After 1, 3, 6, 12 h interval times, cells were washed with PBS, stained
with mitotracker (Red or Deep red) and nuclear dye DAPI (blue) in dark
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and finally imaged under a confocal microscope. The specific binding
and internalization behaviors of FA-coated MSNs in response to various
cell lines were evaluated by the green fluorescence intensity from cells.
The FR-mediated binding and endocytosis behaviors of FITC-MSNs-
FA nanoparticles were further verified by the competitive assays. HeLa
cells were seeded on a 6-well plate at 5×105 cells/well. After 24 h of
attachment, cells were treated with free FA (7.5 μM) prior to the in-
cubation of FITC-MSNs-FA nanoparticles for different time periods (3,
6, 12, 24 h). Then cells were washed with PBS to remove the excess
nanoparticles. All the cells were collected after trypsinization and
centrifugation, and used for flow cytometric analysis. The cellular up-
take efficiency was finally decided by the percentage of FITC-positive
cells related to the control.
5.5. Microscopic analysis of the intracellular localization of peptide-loaded
MSNs-FA nanoparticles
HeLa cells were treated with fluorescence-labeled N9@MSNs-FA
nanodrugs (N9-RB@FITC-MSNs-FA, 33 μg/ml) for 12 h or 24 h prior to
the staining procedures. Then cells were washed several times with PBS
and treated with deep red-mitochondrial tracker for 45min at 37 °C
under dark condition. After removal of the staining solution, cells were
then fixed with 4% paraformaldehyde at 25 °C for 10min, and stained
with DAPI solution (5 μg/ml) in PBS for 15min. The treated cells with
N9-RB@FITC-MSNs-FA could be also pre-fixed with 4% paraformalde-
hyde for 10min, followed by incubation with 0.2% Triton X-100 for
5min, with 3% BSA for 30min, and then with fluorescence-labeled
antibody against the intracellular protein Bcl-2 (deep red) for 2 h at
37 °C condition. The cell nucleus was similarly labeled with DAPI.
Finally, all the above cell samples were observed by a laser confocal
microscope. The intracellular localization behaviors of N9-RB@FITC-
MSNs-FA with mitochondria or Bcl-2 protein could be clearly decided
by the merged fluorescence colors and coincidence areas.
5.6. Bcl-2-dependent localization of N9 peptide with mitochondria
Whether the localization of N9 peptide with mitochondria was in a
Bcl-2-dependent way was further determined by using Bcl-2 gene-
knocked out HeLa cells (Bcl-2-/- Hela). The Bcl-2-/- HeLa cells were
obtained in our laboratory as we previously reported. The procedures
about the cellular internalization were similarly taken as above. HeLa
cells were incubated with a certain concentration of N9-RB@FITC-
MSNs-FA nanodrugs at 37 °C for 1, 3, 6, 12, 24 h. Then the medium was
replaced with preheated (37 °C) medium containing mitotracker. After
incubation for 30min, the cells were washed with PBS and fixed with
4% paraformaldehyde, and stained with DAPI solution (5 μg/ml) in PBS
for 15min. After serval times with washing, the cells were monitored
under a laser confocal microscope (Zeiss Exciter 5).
5.7. Anticancer efficacy of N9@MSNs-FA nanodrugs
The in vitro anticancer efficacy of N9@MSNs-FA nanodrugs to HeLa
and HEK293T cells were respectively determined using the MTT assay.
Free N9 peptide was used as the positive control. The cells were seeded
onto 96-well plate at a density of 5×103 cells/well in a complete MEM
and DMEM medium supplemented with 10% FBS in a humidified 5%
CO2 atmosphere at 37 °C for 24 h. Then the cells were treated with fresh
culture medium containing either free N9 or N9@MSNs-FA at different
MSNs doses ranging from 1 to 200 μg/ml (equivalent to N9 con-
centrations from 0.08 μM to 15.7 μM). The cells were further incubated
for 48 h, and then washed with PBS to remove excess samples. The cells
were followed by incubation with MTT working solution (100μl/well,
200 μg/ml) at 37 °C for another 4 h. Finally, the viability of cells in-
duced by N9 or N9@MSNs-FA was determined by the optical absorp-
tion values at the wavelength of 490 nm on a microplate reader
(Promega Glomax ® Discover) and expressed as the percentage of A490
nm of the treated group compared to that of the untreated group.
5.8. Quantitative analysis of cell apoptosis
Annexin V-FITC apoptosis detection kit (Thermo Fisher Scientifc,
Waltham, MA, USA) was used to quantify the apoptotic and necrotic
cells by a standard fluorescence activated cell sorting (FACS) assay.
HEK293T and HeLa cells were seeded onto 6-well plate on the con-
fluence of 70%-80%, and treated with fresh culture medium containing
either free N9 or N9@MSNs-FA at the same peptide dose of 8.2 μg/ml
(7.8 μM) for 48 h. Then cells were routinely collected, washed twice
with cold PBS, and re-suspended in lX binding buffer to 1×106 cells/
ml. All the cells were stained with 500 μl of binding buffer containing
5 μl of FITC Annexin V solution and 5 μl of PI at room temperature for
15min in the dark. Finally, the cells were detected on a Beckman
Coulter cytoflex within 1 h. The total apoptosis rate of N9 or N9@
MSNs-FA was analyzed using Flowjo software system and calculated
both by the percentages of FITC+PI- - and FITC+PI+-- cells in early and
late apoptotic status.
5.9. Toxicity assessment of nanocarriers using zebrafish models
5.9.1. Zebrafish husbandry
The zebrafish husbandry was performed as previously reported
[34,35], and all the zebrafish experiments were carried out in ac-
cordance with the recommendations in the Guide for the Care and Use
of Laboratory Animals of Xiamen University, China.
5.9.2. Specific experimental methods
The normal fertilized and full-shaped fertilized zebrafish embryos
were selected under a stereomicroscope (Guiguang, China) and ran-
domly divided into eight groups (20 embryos/well, two duplicates) as
reported [36] prior to systemic toxicity testing. MSNs nanoparticles
before and after FA modification (MSNs-NH2 and MSNs-FA) were re-
spectively diluted into different concentrations (10, 50, 200 μg/ml)
with standard dilution water. The above nanoparticles were added into
each well of the 12-well cell culture plate and cultured in a thermostatic
incubator at (27 ± 1) ° C for different time intervals. At the designated
time points (24, 48, 72 h), the alive and dead embryos and the hating
larvaes were recorded. Finally, the biological safety of the above MSNs
nanoparticles against embryonic development of zebrafish was in-
dicated by the mortality rates at 24-72 h, and the hatching rate at 72 h.
5.10. Statistical analysis
The statistical analysis was performed using Student's t-test and one-
way analysis of variance (One-ANOVA) by the least significance dif-
ference (LSD) test (GraphPad Prism 5.0). The difference analyses were
carried out between samples and control or any two samples, which
were considered statistically significant (* or #) for p value < 0.05,
significant (**or ##) and very significant difference (***or ###) for
p < 0.01 and p < 0.001.
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